

					•	diagnostics
PATIENT NAME : KRUNAL V SOL	ANKI	REF. DOCTOR : SELF				
CODE/NAME & ADDRESS : C0001383		CCESSION NO : 0321XCO	01791	AGE/SEX	:32 Years	Male
ARCOFEMI HEALTHCARE LTD (MEDI		ATIENT ID : KRUNM18	30192321	DRAWN	:	
F-703, LADO SARAI, MEHRAULISOU DELHI		LIENT PATIENT ID:		RECEIVED	: 23/03/2024	09:37:40
NEW DELHI 110030	A	BHA NO :		REPORTED	:29/03/2024	15:26:48
8800465156						
Test Report Status <u>Final</u>		Results	Biological	Reference	Interval	Units
MEDI WHEEL FULL BODY HEALTH	I CHECK UP BELO	W 40 MALE				
XRAY-CHEST						
IMPRESSION	N	O ABNORMALITY DETEC	TED			
ECG						
ECG	N	ORMAL SINUS RHYTHM				
MEDICAL HISTORY						
RELEVANT PRESENT HISTORY	N	OT SIGNIFICANT				
RELEVANT PAST HISTORY		OT SIGNIFICANT				
RELEVANT PERSONAL HISTORY		OT SIGNIFICANT				
RELEVANT FAMILY HISTORY						
OCCUPATIONAL HISTORY		OT SIGNIFICANT				
HISTORY OF MEDICATIONS	Ν	OT SIGNIFICANT				
ANTHROPOMETRIC DATA & BMI		6 7				
HEIGHT IN METERS		.67			m	
WEIGHT IN KGS.		7.6	BMZ A M		Kg	
BMI	2	4	Below 18.	5: Underw		<u>/</u> sqmts
				.9: Normal .9: Overwe		
				Above: Ob		
GENERAL EXAMINATION						
MENTAL / EMOTIONAL STATE	N	ORMAL				
PHYSICAL ATTITUDE		ORMAL				
FITISICAL ATILIUDE	IN					
p. v. Espedia	S					Page 1 Of 22

Dr.Priyank Kapadia Physician

Dr.Sahil .N.Shah **Consultant Radiologist**

PERFORMED AT : Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in

View Report

õã View Details

 $\overline{\Sigma}$

t 🔳



Test Report Status



Biological Reference Interval Units

PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321XC001791	AGE/SEX : 32 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KRUNM180192321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/03/2024 09:37:40
NEW DELHI 110030	ABHA NO :	REPORTED :29/03/2024 15:26:48
8800465156		

Results

GENERAL APPEARANCE / NUTRITIONAL	HEALTHY
STATUS	
BUILT / SKELETAL FRAMEWORK	AVERAGE
FACIAL APPEARANCE	NORMAL
SKIN	NORMAL
UPPER LIMB	NORMAL
LOWER LIMB	NORMAL
NECK	NORMAL
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER
THYROID GLAND	NOT ENLARGED
TEMPERATURE	NORMAL
PULSE	86/MIN
RESPIRATORY RATE	NORMAL

Final

CARDIOVASCULAR SYSTEM

BP	130/80 MM HG (SITTING)
PERICARDIUM	NORMAL
APEX BEAT	NORMAL
HEART SOUNDS	S1, S2 HEARD NORMALLY
MURMURS	ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST MOVEMENTS OF CHEST BREATH SOUNDS INTENSITY BREATH SOUNDS QUALITY ADDED SOUNDS NORMAL SYMMETRICAL NORMAL VESICULAR (NORMAL) ABSENT

P. V. Kapadia

Dr.Priyank Kapadia Physician S

Dr.Sahil .N.Shah

Consultant Radiologist



mm/Hg

View Details



View Report

LR No.77500006924461-0321

PERFORMED AT : Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0321XC001791 PATIENT ID : KRUNM180192321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :32 Years Male DRAWN : RECEIVED :23/03/2024 09:37:40 REPORTED :29/03/2024 15:26:48
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

PER ABDOMEN

APPEARANCE	NORMAL
LIVER	NOT PALPABLE
SPLEEN	NOT PALPABLE

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS	NORMAL
CRANIAL NERVES	NORMAL
CEREBELLAR FUNCTIONS	NORMAL
SENSORY SYSTEM	NORMAL
MOTOR SYSTEM	NORMAL
REFLEXES	NORMAL

MUSCULOSKELETAL SYSTEM

SPINE	NORMAL
JOINTS	NORMAL

BASIC EYE EXAMINATION

DISTANT VISION RIGHT EYE WITH GLASSES DISTANT VISION LEFT EYE WITH GLASSES NEAR VISION RIGHT EYE WITHOUT GLASSES NEAR VISION LEFT EYE WITHOUT GLASSES COLOUR VISION

WITH GLASSES NORMAL WITH GLASSES NORMAL WITHIN NORMAL LIMIT WITHIN NORMAL LIMIT NORMAL

SUMMARY

RELEVANT HISTORY RELEVANT GP EXAMINATION FINDINGS NOT SIGNIFICANT NOT SIGNIFICANT

P. V. Kapadia

Dr.Priyank Kapadia Physician

Dr.Sahil .N.Shah **Consultant Radiologist**

PERFORMED AT : Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel: 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in





View Report







PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR : SELF		
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : KRUNM180192321	AGE/SEX : 32 Years Male DRAWN : RECEIVED : 23/03/2024 09:37:40	
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :29/03/2024 15:26:48	

Test Report Status

Results

Biological Reference Interval Units

RELEVANT LAB INVESTIGATIONS RELEVANT NON PATHOLOGY DIAGNOSTICS REMARKS / RECOMMENDATIONS

Final

SGPT:- HIGH NO ABNORMALITIES DETECTED SGPT:- HIGH

ADV:- LOW FAT DIET, REGULAR PHYSICAL EXERCISE

Comments

OUR PANEL DOCTORS FOR NON-PATHOLOGY TESTS:-

CHECK UP DONE BY:- DR. NAMRATA AGRAWAL (M.B.B.S)

REPORT REVIEWED BY:- DR. PRIYANK KAPADIYA (M.B.B.S DNB MEDICINE)

RADIOLOGIST:- DR. SAHIL N SHAH (M.D.RADIOLOGY)

P. V. Copadia

Dr.Priyank Kapadia Physician



Dr.Sahil .N.Shah Consultant Radiologist

PERFORMED AT : Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 4 Of 22









PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR : SELF		
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : KRUNM180192321 CLIENT PATIENT ID:	AGE/SEX :32 Years Male DRAWN : RECEIVED :23/03/2024 09:37:40 REPORTED :29/03/2024 15:26:48	
Test Report Status <u>Final</u>	Results	Units	

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN FATTY LIVER

TMT OR ECHO CLINICAL PROFILE TMT:- NORMAL

Interpretation(s) MEDICAL

HISTORY-HISTORY-THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

P. V. Kapadia

Dr.Priyank Kapadia Physician S

Dr.Sahil .N.Shah Consultant Radiologist

PERFORMED AT : Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 5 Of 22





View Report





PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR :	SELF
	ACCESSION NO : 0321XC001791	AGE/SEX : 32 Years Male
	PATIENT ID : KRUNM180192321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/03/2024 09:37:40
NEW DELHI 110030	ABHA NO :	REPORTED :29/03/2024 15:26:48
8800465156		
Test Report Status Final	Results Biological	Reference Interval Units

HAEMATOLOGY - CBC				
MEDI WHEEL FULL BODY HEALTH CHECK UP B	ELOW 40 MALE			
BLOOD COUNTS, EDTA WHOLE BLOOD				
HEMOGLOBIN (HB) METHOD : PHOTOMETRIC MEASUREMENT	15.1	13.0 - 17.0	g/dL	
RED BLOOD CELL (RBC) COUNT METHOD : COULTER PRINCIPLE	5.55 High	4.5 - 5.5	mil/µL	
WHITE BLOOD CELL (WBC) COUNT METHOD : COULTER PRINCIPLE	6.27	4.0 - 10.0	thou/µL	
PLATELET COUNT METHOD : COULTER PRINCIPLE	335	150 - 410	thou/µL	
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV) METHOD : CALCULATED	47.4	40.0 - 50.0	%	
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	85.4	83.0 - 101.0	fL	
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED	27.2	27.0 - 32.0	pg	
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED	31.8	31.5 - 34.5	g/dL	
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	15.2 High	11.6 - 14.0	%	
MENTZER INDEX METHOD : CALCULATED PARAMETER	15.4			
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM	6.5 Low	6.8 - 10.9	fL	
WBC DIFFERENTIAL COUNT				
NEUTROPHILS METHOD : OPTICAL IMPEDENCE & MICROCSOPY	50	40 - 80	%	
LYMPHOCYTES	42 High	20 - 40	%	

METHOD : OPTICAL IMPEDENCE & MICROCSOPY

Dr.Miral Gajera **Consultant Pathologist**

Page 6 Of 22







PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0321XC001791 PATIENT ID : KRUNM180192321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :32 Years Male DRAWN : RECEIVED :23/03/2024 09:37:40 REPORTED :29/03/2024 15:26:48

Test Report Status <u>Final</u>	Results	Biological Reference Interv	Biological Reference Interval Units		
MONOCYTES	6	2.0 - 10.0	%		
METHOD : OPTICAL IMPEDENCE & MICROCSOPY					
EOSINOPHILS	2	1.0 - 6.0	%		
METHOD : OPTICAL IMPEDENCE & MICROCSOPY					
BASOPHILS METHOD : IMPEDANCE	0	0 - 1	%		
ABSOLUTE NEUTROPHIL COUNT	3.14	2.0 - 7.0	thou/µL		
METHOD : CALCULATED	J.17	2.0 - 7.0			
ABSOLUTE LYMPHOCYTE COUNT	2.63	1.0 - 3.0	thou/µL		
METHOD : CALCULATED PARAMETER					
ABSOLUTE MONOCYTE COUNT	0.38	0.2 - 1.0	thou/µL		
METHOD : CALCULATED PARAMETER					
ABSOLUTE EOSINOPHIL COUNT	0.13	0.02 - 0.50	thou/µL		
METHOD : CALCULATED					
ABSOLUTE BASOPHIL COUNT	0.00 Low	0.02 - 0.10	thou/µL		
METHOD : CALCULATED					
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.2				
METHOD : CALCULATED PARAMETER					

MORPHOLOGY	
RBC	NORMOCYTIC NORMOCHROMIC
METHOD : MICROSCOPIC EXAMINATION	
WBC	NORMAL MORPHOLOGY
METHOD : MICROSCOPIC EXAMINATION	
PLATELETS	ADEQUATE
METHOD : MICROSCOPIC EXAMINATION	
REMARKS	NO PREMATURE CELLS ARE SEEN. MALARIAL PARASITE NOT DETECTED.
METHOD : MICROSCOPIC EXAMINATION	

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

Dr.Miral Gajera Consultant Pathologist



Ο.

View Report

View Details



PERFORMED AT : Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel: 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR : SELF			
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321XC001791 PATIENT ID : KRUNM180192321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :32 Years Male DRAWN : RECEIVED :23/03/2024 09:37:40 REPORTED :29/03/2024 15:26:48		
Test Report Status Final	Results Biologic	cal Reference Interval Units		

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel: 079-48912999,079-48913999,079-48914999 ${\sf Email: customercare.ahmedabad@agilus.in}$









Test Report Status

Final



Biological Reference Interval Units

PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR : S	SELF
		AGE/SEX : 32 Years Male
F-703, LADO SARAI, MEHRAULISOUTH WEST		DRAWN : RECEIVED : 23/03/2024 09:37:40
	ABHA NO :	REPORTED :29/03/2024 15:26:48

Results

	HAEMATOLOGY		
MEDI WHEEL FULL BODY HEALTH C	HECK UP BELOW 40 MALE		
ERYTHROCYTE SEDIMENTATION RA	ATE (ESR),EDTA		
E.S.R METHOD : WESTERGREN METHOD	08	0 - 14	mm at 1 hr
GLYCOSYLATED HEMOGLOBIN(HBA BLOOD	1C), EDTA WHOLE		
HBA1C	5.5	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%

< 116.0

Interpretation(s) ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-TEST DESCRIPTION :-

ESTIMATED AVERAGE GLUCOSE(EAG)

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammator condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

111.2

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

Dr.Miral Gaiera Consultant Pathologist



Page 9 Of 22

View Report

mg/dL

View Details



PERFORMED AT : Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321XC001791 PATIENT ID : KRUNM180192321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :32 Years Male DRAWN : RECEIVED :23/03/2024 09:37:40 REPORTED :29/03/2024 15:26:48	
Test Report Status <u>Final</u>	Results Biologic	al Reference Interval Units	

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.
Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbAIc (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to : 1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results. 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr.Miral Gajera **Consultant Pathologist**

Page 10 Of 22









PERFORMED AT : Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR : SELF			
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : KRUNM180192321 CLIENT PATIENT ID:	AGE/SEX :32 Years Male DRAWN : RECEIVED :23/03/2024 09:37:40 REPORTED :29/03/2024 15:26:48		
8800465156				

Test Report Status Final Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP TYPE A METHOD : TUBE AGGLUTINATION POSITIVE RH TYPE METHOD : TUBE AGGLUTINATION

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel: 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in

Page 11 Of 22

View Report







PATIENT NAME : KRUNAL V SOLANKI		REF. DOCTOR	SELF	
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 032	1XC001791	AGE/SEX : 32 Yea	rs Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KRU	INM180192321	DRAWN :	
F-703, LADO SARAI, MEHRAULISOUTH WEST	CLIENT PATIENT ID:		RECEIVED : 23/03/	2024 09:37:40
DELHI	ABHA NO :		REPORTED :29/03/	
NEW DELHI 110030 8800465156			20,00,	
Test Report Status <u>Final</u>	Results	Biologica	al Reference Interv	al Units
	BIOCHEMISTRY			
MEDI WHEEL FULL BODY HEALTH CHECK UP	BELOW 40 MALE			
GLUCOSE FASTING, FLUORIDE PLASMA				
FBS (FASTING BLOOD SUGAR) METHOD : HEXOKINASE	81	74 - 99		mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA				
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD : HEXOKINASE	126	70 - 140)	mg/dL
LIPID PROFILE WITH CALCULATED LDL, SER		Desirabl		ma (di
CHOLESTEROL, TOTAL	178	Borderlii	e: < 200 neHigh: 200 - 239 or = 240	mg/dL
	129	Borderlin High: 20	e: < 150 neHigh: 150 - 199 00 - 499 h: > or = 500	mg/dL
METHOD : ENZYMATIC, COLORIMETRIC HDL CHOLESTEROL	47	< 40 Lov > or = 6		mg/dL
CHOLESTEROL LDL	105 High	100-129 Borderlin High : 1	< 100 ;imal/above optima ne high : 130-159	mg/dL II:
NON HDL CHOLESTEROL	131 High	Desirabl Above D Borderlin High: 19	e: Less than 130 esirable: 130 - 159 ne High: 160 - 189	
VERY LOW DENSITY LIPOPROTEIN	25.8	< or = 3		mg/dL

yeyen

Dr.Miral Gajera **Consultant Pathologist**

Page 12 Of 22







PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR : SELF				
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321XC	001791	AGE/SEX	:32 Years	Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KRUNM1	80192321	DRAWN	:	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID: ABHA NO :			: 23/03/2024	
NEW DELHI 110030	ABHA NO :		REPORIED	:29/03/2024	15:26:48
8800465156					
Test Report Status <u>Final</u>	Results	Biologica	Reference	e Interval l	Jnits
CHOL/HDL RATIO	3.8	3.3 - 4.4			
LDL/HDL RATIO	2.2	0.5 - 3.0 3.1 - 6.0 Risk >6.0 Higl	Borderline	'Low Risk e/Moderate	

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target. **Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India**

		ici oscici otic cai ulovas	cului un	sease, by Elpie	* 11550clucion of inv		
Risk Category							
Extreme risk group	A.CAD wit	A.CAD with > 1 feature of high risk group					
	B. CAD wit	h > 1 feature of Very hi	igh risk g	roup or recurre	ent ACS (within 1 y	ear) despite LDL-C < or =	
	50 mg/dl or	polyvascular disease					
Very High Risk	1. Establish	ed ASCVD 2. Diabetes	s with 2 r	najor risk facto	ors or evidence of en	d organ damage 3.	
	Familial Ho	mozygous Hypercholes	terolemia	a			
High Risk						o evidence of end organ	
	damage. 3.	CKD stage 3B or 4. 4.	LDL > 1	90 mg/dl 5. Ex	streme of a single ris	sk factor. 6. Coronary	
	Artery Calc	ium - CAC >300 AU. 7	7. Lipopr	otein a >/= 50n	ng/dl 8. Non stenot	ic carotid plaque	
Moderate Risk	2 major AS	CVD risk factors					
Low Risk	0-1 major A	SCVD risk factors					
Major ASCVD (Ath	erosclerotic c	ardiovascular disease)) Risk Fa	ctors			
1. Age $>$ or $=$ 45 years	1. Age $>$ or $=$ 45 years in males and $>$ or $=$ 55 years in females 3. Current Cigarette smoking or tobacco use					tobacco use	
2. Family history of p	remature ASC	CVD		4. High blood	d pressure		
5. Low HDL							
Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.							
Risk Group		Treatment Goals			Consider Drug T	herapy	
		LDL-C (mg/dl)	Non-H	DL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)	
Extreme Risk Group	Category A	<50 (Optional goal					

Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	< OR = 60)		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

Dr.Miral Gajera Consultant Pathologist

Page 13 Of 22

View Report







PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321XC001791	AGE/SEX : 32 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KRUNM180192321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/03/2024 09:37:40
NEW DELHI 110030	ABHA NO :	REPORTED :29/03/2024 15:26:48
8800465156		

Test Report Status Results **Biological Reference Interval** Units **Final** BILIRUBIN, TOTAL 0.59 mg/dL Upto 1.2 0.25 High mg/dL BILIRUBIN, DIRECT Upto 0.2

	olizo iligii	0000.2	iiig/ dE
METHOD : DIAZO COLORIMETRIC BILIRUBIN, INDIRECT	0.34	0.00 - 1.00	mg/dL
TOTAL PROTEIN	7.4	6.4 - 8.3	g/dL
METHOD : COLORIMETRIC			
ALBUMIN	4.9	3.5 - 5.2	g/dL
METHOD : BROMOCRESOL GREEN	2 F		
GLOBULIN	2.5	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO	2.0	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	43 High	0 - 40	U/L
METHOD : IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE	71 High	0 - 41	U/L
ALKALINE PHOSPHATASE METHOD : COLORIMETRIC	81	40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)	34	8 - 61	U/L
	245	125 225	11/1
LACTATE DEHYDROGENASE METHOD : UV ASSAY METHOD	215	135 - 225	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	8	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE	0.96	0.90 - 1.30	mg/dL
METHOD : JAFFE ALKALINE PICRATE			
BUN/CREAT RATIO			
BUN/CREAT RATIO	8.33	5.0 - 15.0	

Dr.Miral Gajera **Consultant Pathologist**



Page 14 Of 22







PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 032	IXC001791 AGE/SEX	:32 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KRUI	M180192321 DRAWN	:
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVE	D :23/03/2024 09:37:40
NEW DELHI 110030	ABHA NO :	REPORTE	D :29/03/2024 15:26:48
8800465156			
Test Report Status <u>Final</u>	Results	Biological Referen	nce Interval Units
URIC ACID, SERUM			
URIC ACID	5.5	3.4 - 7.0	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.4	6.4 - 8.3	g/dL
METHOD : COLORIMETRIC			
ALBUMIN, SERUM			
ALBUMIN	4.9	3.5 - 5.2	g/dL
METHOD : BROMOCRESOL GREEN			
GLOBULIN			
GLOBULIN	2.5	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	137.6	136- 145	mmol/L
POTASSIUM, SERUM	4.66	3.50- 5.10	mmol/L
CHLORIDE, SERUM	107.3 High	98 - 107	mmol/L

Interpretation(s)			
	Sodium	Potassium	Chloride

Dr.Miral Gajera **Consultant Pathologist**

Page 15 Of 22







PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	PATIENT ID : KRUNM180192321 CLIENT PATIENT ID:	AGE/SEX :32 Years Male DRAWN : RECEIVED :23/03/2024 09:37:40 REPORTED :29/03/2024 15:26:48

Test	Report	Status	Final
------	--------	--------	--------------

Results

Biological Reference Interval Units

Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol

sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed,Alimentary Hypoglycemia,Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give vellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic

Dr.Miral Gaiera Consultant Pathologist



View Details



Page 16 Of 22



PERFORMED AT: Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel: 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0321XC001791 PATIENT ID : KRUNM180192321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :32 Years Male DRAWN : RECEIVED :23/03/2024 09:37:40 REPORTED :29/03/2024 15:26:48
Test Report Status Final	Results Biological	Reference Interval Units

hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc. Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels

(hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic

syndrome **Causes of decreased levels**-Low Zinc intake, OCP, Multiple Sclerosis TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin. **Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr.Miral Gaiera Consultant Pathologist

Page 17 Of 22





View Report

View Details



PERFORMED AT: Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel: 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0321XC001791 PATIENT ID : KRUNM180192321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :32 Years Male DRAWN : RECEIVED :23/03/2024 09:37:40 REPORTED :29/03/2024 15:26:48
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

CLINICAL PATH - URINALYSIS			
MEDI WHEEL FULL BODY HEALTH CHECK UP BI	ELOW 40 MALE		
PHYSICAL EXAMINATION, URINE			
COLOR	Yellow		
APPEARANCE	Clear		
CHEMICAL EXAMINATION, URINE			
PH	5.5	4.7 - 7.5	
METHOD : REFLECTANCE SPECTROPHOTOMETRY	4.045		
SPECIFIC GRAVITY	1.015	1.003 - 1.035	
METHOD : REFLECTANCE SPECTROPHOTOMETRY PROTEIN	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED		
GLUCOSE	NOT DETECTED	NEGATIVE	
METHOD : REFLECTANCE SPECTROPHOTOMETRY			
KETONES	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY			
BLOOD	NOT DETECTED	NEGATIVE	
METHOD : REFLECTANCE SPECTROPHOTOMETRY BILIRUBIN	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED	
UROBILINOGEN	NORMAL	NORMAL	
METHOD : REFLECTANCE SPECTROPHOTOMETRY			
NITRITE	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY			
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY			

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION PUS CELL (WBC'S)	NOT DETECTED	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION EPITHELIAL CELLS	3-5	0-5	/HPF

Dr.Miral Gajera Consultant Pathologist



View Report







PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO: 0321XC001791 PATIENT ID : KRUNM180192321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :32 Years Male DRAWN : RECEIVED :23/03/2024 09:37:40 REPORTED :29/03/2024 15:26:48
Test Report Status <u>Final</u>	Results Biologic	cal Reference Interval Units

METHOD : MICROSCOPIC EXAMINATION		
CASTS	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION		
CRYSTALS	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION		
BACTERIA	NOT DETECTED	NOT DETECTED
METHOD : MICROSCOPIC EXAMINATION		
YEAST	NOT DETECTED	NOT DETECTED
METHOD : MICROSCOPIC EXAMINATION		
REMARKS	MICROSCOPIC EXAMINATION OF URINE IS CARRIED OUT C CENTRIFUGED URINARY SEDIMENT.	

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells) Urinary tract infection, urinary tract or kidney stone, tumors or any ki of kidney impairment	
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin Liver disease	
Erythrocytes Urological diseases (e.g. kidney and bladder cancer, urolithiasis), ur tract infection and glomerular diseases	
Leukocytes Urinary tract infection, glomerulonephritis, interstitial nephritis eith acute or chronic, polycystic kidney disease, urolithiasis, contaminati genital secretions	
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or
	bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,
	interaction with Bence-Jones protein
Hyaline casts Physical stress, fever, dehydration, acute congestive heart failure diseases	

Dr.Miral Gajera Consultant Pathologist



Π.







PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR : SELF			
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI		AGE/SEX : 32 Years Male DRAWN : RECEIVED : 23/03/2024 09:37:40 REPORTED : 29/03/2024 15:26:48		

Results

Test Report	Status	<u>Final</u>
--------------------	--------	--------------

Biolo

Biological Reference Interval Units

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in





View Report





PATIENT NAME : KRUNAL V SOLANKI	REF. DOCTOR : SELF			
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0321XC001791 PATIENT ID : KRUNM180192321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :32 Years Male DRAWN : RECEIVED :23/03/2024 09:37:40 REPORTED :29/03/2024 15:26:48		
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units		

PECIALISED CHEMISTRY - HORMONE
PLCIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

THYROID PANEL, SERUM			
ТЗ	152.90	80.0 - 200.0	ng/dL
METHOD : ECLIA			
T4	10.90	5.10 - 14.10	µg/dL
METHOD : ECLIA			
TSH (ULTRASENSITIVE)	1.490	0.270 - 4.200	µIU/mL
METHOD : ECLIA			

Interpretation(s)

Triiodothyronine T3, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Dr.Miral Gajera Consultant Pathologist



View Report

View Details



PERFORMED AT : Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



CODE/NAME & ADDRESS : C000138364ACCESSION NO : 0321XC001791AGE/SEX : 32 YearsMaleARCOFEMI HEALTHCARE LTD (MEDIWHEELPATIENT ID: KRUNM180192321DRAWN:F-703, LADO SARAI, MEHRAULISOUTH WESTCLIENT PATIENT ID:RECEIVED: 23/03/202409:37:40NEW DELHI 110030ABHA NO::REPORTED: 29/03/202415:26:48	

Test	Report	Status	<u>Final</u>
------	--------	--------	--------------

Results

Biological Reference Interval Units

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING 1. It is presumed that the test sample belongs to the patient 5. AGILUS Diagnostics confirms that all tests have been named or identified in the test requisition form. performed or assayed with highest quality standards, clinical 2. All tests are performed and reported as per the safety & technical integrity. 6. Laboratory results should not be interpreted in isolation; turnaround time stated in the AGILUS Directory of Services. 3. Result delays could occur due to unforeseen it must be correlated with clinical information and be circumstances such as non-availability of kits / equipment interpreted by registered medical practitioners only to breakdown / natural calamities / technical downtime or any determine final diagnosis. other unforeseen event. 7. Test results may vary based on time of collection, 4. A requested test might not be performed if: physiological condition of the patient, current medication or i. Specimen received is insufficient or inappropriate nutritional and dietary changes. Please consult your doctor ii. Specimen quality is unsatisfactory or call us for any clarification. 8. Test results cannot be used for Medico legal purposes. iii. Incorrect specimen type iv. Discrepancy between identification on specimen 9. In case of queries please call customer care container label and test requisition form (91115 91115) within 48 hours of the report. **Agilus Diagnostics Ltd** Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



Dr.Miral Gajera Consultant Pathologist



Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in









Page 22 Of 22